Publications by authors named "Lismary Avila-Diaz"
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1-2 Clinical Trial.
Gilda Lemos-Pérez Yinet Barrese-Pérez Yahima Chacón-Quintero Rolando Uranga-Piña Yisel Avila-Albuerne
Vaccines (Basel)
September 2024
Article Synopsis
- * The study found that both vaccines had no severe adverse effects and a high percentage of participants showed increased antibody responses after receiving the booster, with 83.3% for Abdala in Phase 1 and 88.6% in Phase 2.
- * Both vaccines exceeded the immunogenicity goals set by the trial, with significant increases in antibody levels and neutralizing capacity against SARS-CoV-2 variants after the booster dose, indicating strong efficacy.